{"title":"间充质干细胞治疗自身免疫性疾病:未来展望","authors":"G. Pennesi","doi":"10.15406/icpjl.2018.06.00185","DOIUrl":null,"url":null,"abstract":"Mesenchymal Stem Cells (MSC) transplanted into a recipient organism for therapeutic purposes exert their action not only by cell-to-cell contact, but also by secreting soluble factors. Since biological issues and regulatory constrains hamper the use of MSC for clinical purposes, novel approaches should be attempted. In the last years, the feasibility of using MSC-derived micro vesicles as potential mediators carrying tolerogenic molecules has been tested in pre-clinical modes of autoimmune diseases.","PeriodicalId":92215,"journal":{"name":"International clinical pathology journal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mesenchymal stem cell therapy for autoimmune diseases: future Perspectives\",\"authors\":\"G. Pennesi\",\"doi\":\"10.15406/icpjl.2018.06.00185\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mesenchymal Stem Cells (MSC) transplanted into a recipient organism for therapeutic purposes exert their action not only by cell-to-cell contact, but also by secreting soluble factors. Since biological issues and regulatory constrains hamper the use of MSC for clinical purposes, novel approaches should be attempted. In the last years, the feasibility of using MSC-derived micro vesicles as potential mediators carrying tolerogenic molecules has been tested in pre-clinical modes of autoimmune diseases.\",\"PeriodicalId\":92215,\"journal\":{\"name\":\"International clinical pathology journal\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-11-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International clinical pathology journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/icpjl.2018.06.00185\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International clinical pathology journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/icpjl.2018.06.00185","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Mesenchymal stem cell therapy for autoimmune diseases: future Perspectives
Mesenchymal Stem Cells (MSC) transplanted into a recipient organism for therapeutic purposes exert their action not only by cell-to-cell contact, but also by secreting soluble factors. Since biological issues and regulatory constrains hamper the use of MSC for clinical purposes, novel approaches should be attempted. In the last years, the feasibility of using MSC-derived micro vesicles as potential mediators carrying tolerogenic molecules has been tested in pre-clinical modes of autoimmune diseases.